Important considerations in the management of HR+, HER2-negative early breast cancer
The late recurrence of ER+ breast cancer
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Dr. Mamounas on Recurrence Rates in Breast Cancer
Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer
What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+
How to Understand Late Recurrence of Hormone Receptor-Positive Breast Cancer
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer
Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...
Optimizing treatment in patients with early-stage HER2-positive breast cancer
Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert ...
Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Ca...
Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer
Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...
Treatment Options for HER2-Negative Breast Cancer
New FDA-Approved Targeted Drug for Treatment-Resistant, ER Positive HER2 Negative Breast Cancer
How long can you expect to live with metastatic breast cancer?
Management of premenopausal HR+/HER2- breast cancer with micro-metastasis
